Tiziana Life Sciences CEO to Present at Annual BIO CEO & Investor Conference
Management will be available for 1x1 investor meetings on
Tiziana is developing proprietary and novel formulation technologies to enable alternative routes of immunotherapy. Tiziana’s lead programs are focused on developing the fully-human antibody, foralumab via varied modes of delivery, alone or in combination to address different therapeutic indications. Data from clinical and animal studies support the underlying hypothesis that nasally administered foralumab acts via site-targeted immunomodulation. This concept was further validated by clinical data from a recently completed study with nasally administered foralumab in COVID-19 patients.
Further, interim data from a clinical study in a patient with secondary progressive multiple sclerosis (SPMS) also indicated that the treatment was not only well-tolerated, but it also produced clinical response after three months of treatment. Consequently, the
A similar mechanism of site-targeted immunomodulation exists for orally administered foralumab for treatment of inflammatory bowel diseases (IBD) such as Crohn’s Disease and ulcerative colitis. Recently, Tiziana submitted an amended Investigational Drug Application (IND) for a Phase 1b study evaluating safety and tolerability of orally administered foralumab in patients with mild-to-moderate Crohn’s Disease. The study is expected to conclude in the fourth quarter of this year.
About BIO and the BIO CEO and Investor Conference
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Tel: (646) 970-4681
+44 (0) 207 495 2379
Source: Tiziana Life Sciences Ltd.